Becatecarin (BioDeep_00000838005)

   


代谢物信息卡片


Becatecarin

化学式: C33H34Cl2N4O7 (668.1804434000001)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCN(CC)CCN1C(=O)C2=C3C4=C(C(=CC=C4)Cl)NC3=C5C(=C2C1=O)C6=C(N5C7C(C(C(C(O7)CO)OC)O)O)C(=CC=C6)Cl
InChI: InChI=1S/C33H34Cl2N4O7/c1-4-37(5-2)12-13-38-31(43)22-20-15-8-6-10-17(34)24(15)36-25(20)27-21(23(22)32(38)44)16-9-7-11-18(35)26(16)39(27)33-29(42)28(41)30(45-3)19(14-40)46-33/h6-11,19,28-30,33,36,40-42H,4-5,12-14H2,1-3H3/t19-,28-,29-,30-,33-/m1/s1

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent

同义名列表

1 个代谢物同义名

Becatecarin



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Afshin Dowlati, James Posey, Ramesh K Ramanathan, Linda Rath, Pingfu Fu, Amitabh Chak, Smitha Krishnamurthi, Joanna Brell, Stephen Ingalls, Charles L Hoppel, Percy Ivy, Scot C Remick. Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. Cancer chemotherapy and pharmacology. 2009 Dec; 65(1):73-8. doi: 10.1007/s00280-009-1005-x. [PMID: 19399502]
  • Gautam Borthakur, Yesid Alvarado, Farhad Ravandi-Kashani, Jorge Cortes, Zeev Estrov, Stefan Faderl, Percy Ivy, Carlos Bueso-Ramos, B Nebiyou Bekele, Francis Giles. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer. 2008 Jul; 113(2):360-6. doi: 10.1002/cncr.23559. [PMID: 18473351]
  • Anne-Marie Langevin, Mark Bernstein, John G Kuhn, Susan M Blaney, Percy Ivy, Junfeng Sun, Zhengjia Chen, Peter C Adamson. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatric blood & cancer. 2008 Mar; 50(3):577-80. doi: 10.1002/pbc.21274. [PMID: 17610262]
  • Maha Hussain, Ulka Vaishampayan, Lance K Heilbrun, Vikash Jain, Patricia M LoRusso, Percy Ivy, Lawrence Flaherty. A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer. Investigational new drugs. 2003 Nov; 21(4):465-71. doi: 10.1023/a:1026259503954. [PMID: 14586215]
  • Anne-Marie Langevin, Steven D Weitman, John G Kuhn, Susan T Weintraub, Sylvain Baruchel, Wayne Furman, Mark Bernstein, Susan Blaney, Teresa Vietti. Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group study. Journal of pediatric hematology/oncology. 2003 Jul; 25(7):526-33. doi: 10.1097/00043426-200307000-00006. [PMID: 12847318]
  • Joseph Merchant, Kendra Tutsch, Amy Dresen, Rhoda Arzoomanian, Dona Alberti, Chris Feierabend, Kim Binger, Rebecca Marnoccha, James Thomas, Jim Cleary, George Wilding. Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Jul; 8(7):2193-201. doi: NULL. [PMID: 12114420]
  • A W Tolcher, S G Eckhardt, J Kuhn, L Hammond, G Weiss, J Rizzo, C Aylesworth, M Hidalgo, A Patnaik, G Schwartz, S Felton, E Campbell, E K Rowinsky. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Jun; 19(11):2937-47. doi: 10.1200/jco.2001.19.11.2937. [PMID: 11387367]
  • A Dowlati, C L Hoppel, S T Ingalls, S Majka, X Li, N Sedransk, T Spiro, S L Gerson, P Ivy, S C Remick. Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Apr; 19(8):2309-18. doi: 10.1200/jco.2001.19.8.2309. [PMID: 11304785]